Therefore, bromocriptine may prevent obesity-induced glucose intolerance via peripheral mechanisms including promotion of hepatic ER homeostasis, but not central dopamine D2 receptor-mediated mechanisms. The gene discussed is DRD2; the disease is obesity due to melanocortin 4 receptor deficiency.